Scpharmaceuticals

Yahoo Finance • 9 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZIMV, ARIS, SCPH on Behalf of Shareholders

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story

Yahoo Finance • 10 days ago

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – GTLS, SCPH, VTLE, and VRNT

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in t... Full story

Yahoo Finance • 27 days ago

Unusual volume stocks in Friday's session

Which stocks have an unusual volume on Friday? [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT SOGP [https://www.chartmill.com/stock/quote/SOGP/profile] 10.59% 10.76M shares of SOUND GROUP INC (NASDAQ:SOGP [ht... Full story

Yahoo Finance • 28 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMXI, HBI, VTLE, SCPH on Behalf of Shareholders

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 28 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)

BALA CYNWYD, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • last month

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • last month

MannKind stock price target raised to $8 by RBC on scPharmaceuticals deal

Investing.com - RBC Capital raised its price target on MannKind (NASDAQ:MNKD) to $8.00 from $7.00 on Tuesday, while maintaining an Outperform rating following the company’s acquisition of scPharmaceuticals (NASDAQ:SCPH). InvestingPro data... Full story

Yahoo Finance • last month

SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind

MONSEY, N.Y., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc. (Nasdaq: SCPH) (“SCPH”) to MannKind Corporation (“MannKind”) for $5.35 per share in... Full story

Yahoo Finance • last month

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment o... Full story

Yahoo Finance • last month

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today... Full story

Yahoo Finance • 2 months ago

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remai... Full story

Yahoo Finance • 2 months ago

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmace... Full story

Yahoo Finance • 6 months ago

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA... Full story

Yahoo Finance • 6 months ago

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmac... Full story

Yahoo Finance • 7 months ago

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be a... Full story

Yahoo Finance • 8 months ago

scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced... Full story

Yahoo Finance • 2 years ago

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLIN... Full story

Yahoo Finance • 2 years ago

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,... Full story

Yahoo Finance • 2 years ago

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to opt... Full story

Yahoo Finance • 2 years ago

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency confirms no additional clinical data r... Full story